Acute Ischemic Stroke Clinical Trial
Official title:
Mechanical Thrombectomy in Acute Ischemic Stroke Beyond the Time of Window: Non Randomized Controlled Clinical Trial
Background: intravenous alteplase appears to be much less effective at opening proximal
occlusions of the major intracranial arteries, which account for more than one third of cases
of acute anterior-circulation stroke and expanding time window using mechanical thrombectomy
can improve clinical outcome in patients that would have only received conservative
treatment.
The aim of this work is to evaluate the effectiveness of endovascular therapy within 24 hours
of symptom onset and to compare clinical outcome of endovascular therapy with the standard
medical therapy at the end of 3rd month follow up.
Material and Methods 57 subjects presenting with an acute ischemic stroke caused by occlusion
of the proximal middle cerebral artery (M1 segment) or Internal carotid artery ( ICA segment)
within 24 hours from symptom onset as documented by Ct, and or MRI perfusion were recruited
consecutively from 2 University hospitals Ain shams University Hospital (32 Patients) and
Aswan University (25 patients). Assessment of each subject was performed using NIHSS, and
MRS, Aspect score, before intervention. Follow up was done using the same clinical scale one
week and the 3 month after the onset.
Primary outcome NIHSS and MRS at the end of 3 month after the onset. secondary outcome
complications (cerebral Hge) and death at 3 months.
Background Expanding time window using the emerging technologies for mechanical thrombectomy
can improve chances of achieving successful thrombectomy and improve clinical outcome in
patients that would have only received conservative treatment. The aim of this work is to
evaluate the effectiveness and safety of endovascular therapy within 24 hours of symptom
onset and to compare clinical outcome of endovascular therapy and standard medical therapy at
the end of 3rd month.
Subjects and Methods:
This is a multicenteric case-control clinical trial (Ain shams and Aswan university
hospitals), comparing clinical improvement and mortality/morbidity in patients presenting
with acute ischemic stroke stroke caused by occlusion of the proximal middle cerebral artery
(M1 segment) or Internal carotid artery (distal ICA segment) within 24 hours from symptom
onset.
Onset of stroke was defined as time they were last known to be well. Ischemic stroke is
characterized by the sudden loss of blood circulation to an area of the brain, resulting in a
corresponding loss of neurologic function. It included 57 patients with acute ischemic stroke
due to large vessel occlusion (LVO) admitted either to neurology department of Ain shams
university hospitals or Aswan university hospitals between during the period from Jan 2019
and August 2019
All patients were subjected to the following:
A) Clinical assessment:
Full history taking with special emphasis upon: Age and Sex of the patient, onset of
symptoms; onset is defined as the point in time the patient was last seen well, presence of
vascular risk factors, namely: diabetes mellitus, hypertension, cardiac diseases,
dyslipidemia and smoking. History of receiving drugs prior to arrival to the hospital,
especially anti-coagulants, and anti-platelets & IV thrombolytics.
Complete general and neurological assessment including: complete general examination
including blood pressure measurement using mercurial sphygmomanometer and random blood sugar
assessment, neurological examination on admission with NIHSS assessment to determine initial
NIHSS, neurological deficit was measured using (NIHSS) obtained on discharge and on day 90
with the modified Rankin Scale (mRS) measured on discharge and after 3 months (Bonita and
Beaglehole, 1988). A standard 12-lead ECG to delineate presence of ischemic changes or
arrhythmias was also done Routine ER laboratory investigations including: complete blood
count and coagulation profile and serum urea and creatinine.
Hypertension was defined as self-report of hypertension with antihypertensive medication use,
and/or systolic blood pressure greater than or equal to 140 mm Hg, and/or diastolic blood
pressure greater than or equal to 90 mm Hg. Diabetes was defined as being on treatment for
diabetes by self-report with antidiabetic drugs and/or having a fasting glucose level greater
than or equal to 126 mg/dL, plasma glucose ≥ 200 mg/dl 2 h after a 75-g oral glucose load as
in a glucose tolerance test, or glycated hemoglobin (HbA1C) ≥ 6.5%. Patients with past or
current history of smoking were categorized as smokers. Dyslipidemia was defined as serum
total cholesterol (TC) > 240, serum LDL-c > 160, serum triglycerides (TAG) > 200 and/or serum
HDL-c < 40 (WHO 2006).
B) Radiological assessment:
Early ischemic changes and collateral circulation were assessed with the Alberta stroke
program for early computed tomography (CT) ischemic score (ASPECTS) and with computed
tomography angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction
angiography (DSA) for localization of the LVO.
N.B: a CT scan was routinely performed between 24 and 36 h after treatment or before in case
of any neurological worsening (≥4-point increase in NIHSS score) occurred.
Procedure of endovascular intervention:
All patients in the 1st group (vascular intervention group) underwent primary thrombectomy
with either the Trevo (TR) stent or the Solitaire (ST) stent (according to the availability)
within the first 24 hours of symptoms onset.
All procedures were performed under the investigator's institutional mild sedation protocol.
Some cases needed general anesthesia.
Favorable outcome was defined as achieving functional independence "mRS of 0,1or 2 in 3
months, poor outcome was defined as mRS of 3-5. Treatment starting is defined as femoral
puncture.
Vascular recanalization was defined as thrombolysis in cerebral ischemia (TICI) score.
Successful recanalization was defined as TICI grade 2b to 3.
Established device-related complications, namely, vascular perforation, arterial dissection,
or embolization, were systematically collected. Symptomatic intracranial hemorrhage was
defined as a hemorrhagic transformation on the 24-h computed tomography (CT) scan related to
the deterioration in the patient's clinical condition in the judgment of the clinical
investigator.Statistical analysis:
Statistical analysis was performed using the Statistical Package for the Social Sciences (IBM
SPSS statistics V23).
Adjusted for age group (1=<70, 2= ≤70 years), Sex (female=0 or male=1), Diabetes mellitus
(yes=1 or no=0), Hypertension (yes=1 or no=0),Cardiac (AF=1, IHD=2, Rheumatic heart=3, normal
=4, AF +IHD =5) Smoking (yes=1 or no=0), Dyslipidemia (yes=1 or no=0), (B, correlation
coefficient; CI, confidence interval; OR, odds ratio; SE, standard error; Wald statistics for
logistic regression analysis.
The outcome of interest was the change in NIHSS and mRS scores throughout 90 days. Continuous
variables are expressed as mean + standard deviation and categorical variables with
percentage of occurrence. For comparison of continuous variables, the Mann-Whitney test was
used between-group comparison. Chi Square test was used for analysis of proportions. A p
Value <0.05 was the threshold for statistical significance.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |